These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11302493)

  • 21. Non-thiol farnesyltransferase inhibitors: N-(4-Acylamino-3-benzoylphenyl)-4-nitrocinnamic acid amides.
    Sakowski J; Sattler I; Schlitzer M
    Bioorg Med Chem; 2002 Feb; 10(2):233-9. PubMed ID: 11741771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.
    Gwaltney SL; O'Connor SJ; Nelson LT; Sullivan GM; Imade H; Wang W; Hasvold L; Li Q; Cohen J; Gu WZ; Tahir SK; Bauch J; Marsh K; Ng SC; Frost DJ; Zhang H; Muchmore S; Jakob CG; Stoll V; Hutchins C; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1363-6. PubMed ID: 12657283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new class of highly potent farnesyl diphosphate-competitive inhibitors of farnesyltransferase.
    Aoyama T; Satoh T; Yonemoto M; Shibata J; Nonoshita K; Arai S; Kawakami K; Iwasawa Y; Sano H; Tanaka K; Monden Y; Kodera T; Arakawa H; Suzuki-Takahashi I; Kamei T; Tomimoto K
    J Med Chem; 1998 Jan; 41(2):143-7. PubMed ID: 9457237
    [No Abstract]   [Full Text] [Related]  

  • 24. Potent, non-thiol inhibitors of farnesyltransferase.
    Breslin MJ; deSolms SJ; Giuliani EA; Stokker GE; Graham SL; Pompliano DL; Mosser SD; Hamilton KA; Hutchinson JH
    Bioorg Med Chem Lett; 1998 Dec; 8(23):3311-6. PubMed ID: 9873725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones.
    Mitsch A; Böhm M; Wissner P; Sattler I; Schlitzer M
    Bioorg Med Chem; 2002 Aug; 10(8):2657-62. PubMed ID: 12057654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of farnesyltransferase: 5-arylacryloylaminobenzophenones show antimalarial activity.
    Wiesner J; Ortmann R; Mitsch A; Wissner P; Sattler I; Jomaa H; Schlitzer M
    Pharmazie; 2003 Apr; 58(4):289-90. PubMed ID: 12749417
    [No Abstract]   [Full Text] [Related]  

  • 27. Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase.
    Dinsmore CJ; Bergman JM; Wei DD; Zartman CB; Davide JP; Greenberg IB; Liu D; O'Neill TJ; Gibbs JB; Koblan KS; Kohl NE; Lobell RB; Chen IW; McLoughlin DA; Olah TV; Graham SL; Hartman GD; Williams TM
    Bioorg Med Chem Lett; 2001 Feb; 11(4):537-40. PubMed ID: 11229765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-thiol farnesyltransferase inhibitors: utilization of the near aryl binding site by 5-arylacetylaminobenzophenones.
    Mitsch A; Böhm M; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2004 Apr; 337(4):213-8. PubMed ID: 15065081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kurasoins A and B, new protein farnesyltransferase inhibitors produced by Paecilomyces sp. FO-3684. I. Producing strain, fermentation, isolation, and biological activities.
    Uchida R; Shiomi K; Inokoshi J; Masuma R; Kawakubo T; Tanaka H; Iwai Y; Omura S
    J Antibiot (Tokyo); 1996 Sep; 49(9):932-4. PubMed ID: 8931728
    [No Abstract]   [Full Text] [Related]  

  • 30. Farnesyltransferase inhibitors.
    Adjei AA
    Cancer Chemother Biol Response Modif; 2001; 19():149-64. PubMed ID: 11686012
    [No Abstract]   [Full Text] [Related]  

  • 31. 4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.
    Angibaud P; Saha AK; Bourdrez X; End DW; Freyne E; Lezouret P; Mannens G; Mevellec L; Meyer C; Pilatte I; Poncelet V; Roux B; Smets G; Van Dun J; Venet M; Wouters W
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4361-4. PubMed ID: 14643326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
    Koblan KS; Kohl NE; Omer CA; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A; Gibbs JB
    Biochem Soc Trans; 1996 Aug; 24(3):688-92. PubMed ID: 8878827
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads.
    Perola E; Xu K; Kollmeyer TM; Kaufmann SH; Prendergast FG; Pang YP
    J Med Chem; 2000 Feb; 43(3):401-8. PubMed ID: 10669567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mode of action of farnesyltransferase inhibitors.
    Prendergast GC
    Lancet Oncol; 2000 Oct; 1():73. PubMed ID: 11905670
    [No Abstract]   [Full Text] [Related]  

  • 35. Discovery and structure-activity relationships of novel piperidine inhibitors of farnesyltransferase.
    Nara S; Tanaka R; Eishima J; Hara M; Takahashi Y; Otaki S; Foglesong RJ; Hughes PF; Turkington S; Kanda Y
    J Med Chem; 2003 Jun; 46(12):2467-73. PubMed ID: 12773050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-cyanocinnamide derivatives: a new family of non-peptide, non-sulfhydryl inhibitors of Ras farnesylation.
    Poradosu E; Gazit A; Reuveni H; Levitzki A
    Bioorg Med Chem; 1999 Aug; 7(8):1727-36. PubMed ID: 10482464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3,8-Diazabicyclo[3.2.1]octan-2-one peptide mimetics: synthesis of a conformationally restricted inhibitor of farnesyltransferase.
    Dinsmore CJ; Bergman JM; Bogusky MJ; Culberson JC; Hamilton KA; Graham SL
    Org Lett; 2001 Mar; 3(6):865-8. PubMed ID: 11263902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Inhibitors of farnesyltransferase: a new approach for development of potential cancer drugs].
    Schlitzer M
    Pharm Unserer Zeit; 1998 Nov; 27(6):278-88. PubMed ID: 9894422
    [No Abstract]   [Full Text] [Related]  

  • 39. Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives.
    Gwaltney SL; O'Connor SJ; Nelson LT; Sullivan GM; Imade H; Wang W; Hasvold L; Li Q; Cohen J; Gu WZ; Tahir SK; Bauch J; Marsh K; Ng SC; Frost DJ; Zhang H; Muchmore S; Jakob CG; Stoll V; Hutchins C; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1359-62. PubMed ID: 12657282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability.
    Tong Y; Lin NH; Wang L; Hasvold L; Wang W; Leonard N; Li T; Li Q; Cohen J; Gu WZ; Zhang H; Stoll V; Bauch J; Marsh K; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2003 May; 13(9):1571-4. PubMed ID: 12699757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.